Boston Scientific Archives - Page 7 of 19

Boston Scientific stock rises before hours on Street-beating Q2

Boston Scientific (NYSE:BSX) shares were up before hours today on second-quarter results that topped the consensus forecast.

Shares of BSX were up 5.11% at $39.90 per share in pre-market trading.

The Marlborough, Massachusetts-based company posted profits of $246 million, or 17¢ per share, on sales of $3.24 billion for the three months ended June 30, 2022, for a 43% bottom-line gain on sales growth of 5.4%.

Adjusted to exclude one-time items, earnings per share were 44¢, 2¢ ahead of Wall Street, where analysts were looking for sales of $3.22 billion.

Each of Boston Scientific’s specific business arms saw year-over-year revenue growth for the quarter, bar its neuromodulation business (down 3.4%). Urology and pelvic health posted the strongest performance (revenues rose 13.4%), while cardiology (within the MedSurg segment) grew 7.6%. MedSurg saw a revenue rise of 4.5% overall.

“We had another quarter of excellent performance, a te…

The biggest medtech personnel moves so far in 2022

In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit.

At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. Throughout just over half of 2022, we’ve already seen a slew of major moves around some of the space’s most powerful players.

Here is a list of some of the biggest personnel changes in medtech so far in 2022:

3M’s healthcare president retires 3M Health Care Business Group President Mojdeh Poul [Image courtesy of 3M]Mojdeh Poul, the president of 3M’s healthcare business, announced in May that she would retire from the position and her retirement was made effective on July 1.

Poul joined 3M in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions, including infection prevention, 3M Canada, and sa…

Boston Scientific to build new plant outside Atlanta

[Image courtesy of Google]Boston Scientific (NYSE:BSX) will build a new manufacturing and supply chain facility in the Atlanta suburb of Johns Creek, Georgia Gov. Brian Kemp announced today.

Kemp’s office said the $62.5 million investment will bring roughly 340 new jobs to the Peach State over the next seven years.

“As home to some of the leading universities and technical colleges in the country, Georgia produces top talent for growing fields like the life sciences industry,” Kemp said in a news release. “Boston Scientific will find well-educated, well-trained, and hardworking Georgians who are eager to support the company’s life-changing work to fill these new positions. I look forward to seeing the impact of this expansion here in Georgia and far beyond as they keep the Peach State on the cutting edge of medical science.”

Boston Scientific purchased Georgia-based EndoChoice in 2016 and already employs about 300 people in Geo…

How medical device makers companies are responding to abortion bans

The front of U.S. Supreme Court in Washington, D.C. (Adobe stock photo)

Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access.

Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately.

Some medtech companies are not using the word “abortion” in their statements to news media.

Here is what we’re finding out at MassDevice and Medical Design & Outsourcing:

Medtronic

“As a healthcare company, we are committed to ensuring access to quality healthcare, and that starts first and foremost with our people. We are expanding our benefits policies to enable access to critical healthcare services for our U.S. employees. The new benefit will allow for reimbursement of travel, relocation, and legal expenses and …

They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Get the full story at our sister site, Medical Design & Outsourcing.

Boston Scientific to acquire majority stake in M.I. Tech

Boston Scientific (NYSE:BSX) announced today that it agreed with Synergy Innovation to purchase its majority stake in M.I. Tech.

Marlborough, Massachusetts-based Boston Scientific will acquire a stake totaling approximately 64% in the publicly traded, Korea-based manufacturer and distributor of medical devices for endoscopic and urologic procedures.

According to a news release, M.I. Tech created the Hanarostent family of conformable, non-vascular, self-expanding metal stents, which Boston Scientific has distributed in Japan since 2015. Hanarostent technology features a hook-cross nitinol design for providing a natural and flexible fit within a patient’s anatomy, along with flared ends to help prevent stent migration.

The purchase price for the agreement includes approximately KRW 14,500 per share, which represents a total of KRW 291.2 billion or approximately $230 million at current exchange rates, subject to closing adjustments.

Boston Scie…

Study supports Boston Scientific’s Acurate neo2 aortic valve system

Acurate Neo2 [Image from Boston Scientific]New registry data demonstrates positive hemodynamic performance and clinical outcomes with the Boston Scientific (NYSE:BSX) Acurate neo2.

Dr. Andrea Scotti of the Montefiore Medical Center (New York) presented data on the current-generation aortic valve system at TVT: The Structural Heart Summit. It was simultaneously published in EuroIntervention.

In an investigator-driven study, retrospective registry data from 2,026 patients across 34 European centers compared outcomes with the previous generation Acurate neo valve from the NEOPRO registry (1,263 patients in 18 centers) with outcomes for the Acurate neo2 valve from the NEOPRO2 registry (763 patients in 16 centers).

Results demonstrated a significant reduction in moderate or severe paravalvular aortic regurgitation (PAR) for the Acurate neo2 valve 2% vs. 5% with Acurate neo), meeting the primary endpoint with a higher Valve Academic Research Consortium 3 (VARC-3)…

What is pulsed-field ablation? Here’s what you need to know

Top experts at Boston Scientific, Medtronic and Acutus Medical shared insights about pulsed-field ablation’s potential at DeviceTalks Boston. Part of the Farapulse pulsed-field ablation system, the Farawave single-shot catheter is designed to create durable and circumferential lesions. [Image courtesy of Boston Scientific]Pulsed-field ablation is a non-thermal method for cardiac ablation that has the potential to positively disrupt the way atrial fibrillation is treated.

PFA’s roots go back to the dc ablation tech of the 1980s. These days, PFA generally involves high-voltage electric pulses from a catheter-delivered electrode or electrodes, delivered each at a tiny fraction of a second. Its potential advantages versus radiofrequency ablation or cryoablation include the characteristic that heart muscle tissue can be especially susceptible to it, while other types of surrounding tissue are injury resistant.

It’s hard these days to find a cardiac device company…

Boston Scientific opens new office in Dubai

Boston Scientific has officially opened its third Middle Eastern office location, located in TECOM Group’s Dubai Science Park (DSP) in the United Arab Emirates.

Eric Thepaut, Executive Vice President and President EMEA at Boston Scientific, said in a Dubai government news release posted yesterday that the company’s investments in the Middle East and North Africa region are significant and far-reaching.

“Strengthening our presence in the region will enable our teams to operate more efficiently and raise awareness of our innovative solutions for a wide range of therapy areas,” Thepaut said.

Tarek El Rahbani, Boston Scientific’s senior regional director, Middle East and Africa, said growth emerging markets are a strategic priority. “This is the part of the world with huge growth potential, there are millions of patients in need of our innovative therapies.

Marwan Abdulaziz Janahi, Managing Director of Dubai Science Park,…

Boston Scientific’s Acurate Neo2 valve performs well in studies

Acurate Neo2 [Image from Boston Scientific]Boston Scientific (NYSE:BSX) announced positive outcomes from studies of its Acurate Neo2 aortic valve system.

Initial outcomes from the Neo-Align study of 170 patients who underwent transcatheter aortic valve implantation (TAVI) with Acurate Neo2 using a novel implant technique to attempt commissural alignment of the prosthetic and native valves demonstrated that commissural alignment can be achieved safely, effectively and quickly.

Data showed that 97% of patients had no significant misalignment (80% none, 17% mild, 1.2% moderate and 1.8% severe) and the average alignment time of 92 seconds had a minimal impact on procedure duration, according to Boston Scientific. Post-procedure and 30-day safety events were consistent with expected TAVI complication rates, while small manipulations of the delivery system in the ascending aorta did not adversely impact safety outcomes.

The company also reported new findings from…

Boston Scientific co-founder Peter Nicholas is dead at 80

[Image from Boston Scientific]Boston Scientific (NYSE:BSX) co-founder and former CEO Peter M. Nicholas has passed away at the age of 80, the company said.

Nicholas, who was a few days away from his 81st birthday, “passed away peacefully,” according to the company’s tribute, on May 14.

“As a pioneer who helped shape the field of minimally invasive surgery, Pete Nicholas is remembered worldwide for his contribution to vastly improved patient outcomes and equally impressive increases in healthcare efficiency,” Boston Scientific Chair and CEO Mike Mahoney said in the tribute. “Within the Boston Scientific family, Pete was also a lifelong mentor, motivator and friend to hundreds of employees.”

Nicholas and co-founder John Abele formed a partnership in 1978 and, in 1979, created Boston Scientific. Nicholas had spent 10 previous years working in sales, marketing and general management at Eli Lilly before becoming GM of the medical products …

How Boston Scientific uses clinical feedback to advance innovation

Put simply, the reason most people enter the medtech space is to make a big difference in the lives of patients.

However, the process isn’t always straightforward,

That’s according to Boston Scientific (NYSE:BSX) SVP of Urology and Pelvic Health Meghan Scanlon. Speaking on the “How Boston Scientific uses clinical feedback to advance innovation” panel at DeviceTalks Boston last week, Scanlon explained how vital the early stages of product development can be.

“Early on, have a strong hypothesis for what your value proposition is going to be,” Scanlon said. “But, don’t go etch it in stone tablets. Use a pencil or an erasable marker and constantly test and validate it. Have an understanding of what your evidence generation plan is going to be over time and don’t let the pursuit of perfection be the enemy of progress.”

Scanlon was joined by Boston Scientific VP of Corporate Digital and Patient & Referrer Marketin…